Annexes to COM(2023)191 - Stepping up EU actions to combat antimicrobial resistance in a One Health approach - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
| dossier | COM(2023)191 - Stepping up EU actions to combat antimicrobial resistance in a One Health approach. |
|---|---|
| document | COM(2023)191  |
| date | June 13, 2023 |
(91) https://health.ec.europa.eu/antimicrobial-resistance/events_en?f%5B0%5D=topic_topic%3A173 .
(92) https://www.efsa.europa.eu/eu .
(93) https://www.ecdc.europa.eu/en .
(94) https://www.ema.europa.eu/en .
(95) https://www.eea.europa.eu/about-us .
(96) https://echa.europa.eu/ .
(97) https://health.ec.europa.eu/system/files/2023-02/international_ghs-report-2022_en.pdf .
(98) https://www.who.int/news-room/questions-and-answers/item/pandemic-prevention--preparedness-and-response-accord .
(99) https://www.fao.org/home/en .
(100) https://www.unep.org/ .
(101) https://www.woah.org/en/home/ .
(102) https://www.who.int/ .
(103) Regulation (EU) 2016/429 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases and amending and repealing certain acts in the area of animal health (‘Animal Health Law’) (OJ L 084 31.3.2016, p. 1) .
(104) Council Recommendation 2018/C 466/01 of 7 December 2018 on Strengthened Cooperation against Vaccine Preventable Diseases (OJ C 466, 28.12.2018, p. 1) .
(105) Regulation (EU) 2021/2115 of the European Parliament and of the Council of 2 December 2021 establishing rules on support for strategic plans to be drawn up by Member States under the common agricultural policy (CAP Strategic Plans) and financed by the European Agricultural Guarantee Fund (EAGF) and by the European Agricultural Fund for Rural Development (EAFRD) and repealing Regulations (EU) No 1305/2013 and (EU) No 1307/2013 (OJ L 435, 6.12.2021, p. 1) .
(106) https://oceans-and-fisheries.ec.europa.eu/funding/emfaf_en .
(107) Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions Strategic guidelines for a more sustainable and competitive EU aquaculture for the period 2021 to 2030 COM(2021) 236 final .
(108) DNA engineering techniques limited to the use of species that have undergone a risk assessment with favourable outcome.
(109)
https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02 .
(110) https://www.who.int/publications/i/item/2021-aware-classification .
(111) https://food.ec.europa.eu/horizontal-topics/official-controls-and-enforcement/legislation-official-controls/better-training-safer-food_en .
(112) CP-p-23-16 Support innovation and access to antimicrobials.
(113) https://www.who.int/initiatives/glass .
(114) https://www.ippc.int/en/ .
(115) https://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXC%2B61-2005%252FCXC_061e.pdf .
(116) https://www.fao.org/fao-who-codexalimentarius/sh-proxy/ar/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXG%2B94-2021%252FCXG_94e.pdf .
(117) https://www.who.int/news-room/questions-and-answers/item/pandemic-prevention--preparedness-and-response-accord .
(118) https://apps.who.int/gb/ebwha/pdf_files/EB144/B144_19-en.pdf .
(119)
https://www.fao.org/antimicrobial-resistance/quadripartite/the-platform/en/ .
(120) https://europa.eu/capacity4dev/tei-jp-tracker/tei/sustainable%C2%A0health-security-africa .
(121)
https://mptf.undp.org/fund/amr00 .
(122) https://research-and-innovation.ec.europa.eu/research-area/health/edctp_en .
Top
EUROPEAN COMMISSION
Brussels, 26.4.2023
COM(2023) 191 final
ANNEXES
to the
Proposal for a COUNCIL RECOMMENDATION
on stepping up EU actions to combat antimicrobial resistance in a One Health approach
{SWD(2023) 190 final}
ANNEX
Member States contributions to reach EU recommended targets set out in point E of this Recommendation 1 .
1.National recommended targets on total consumption of antibiotics in the community and hospital sectors combined, including in long-term care facilities (DDD per 1000 inhabitants per day)
Member State | Total consumption of antibiotics in the community and, hospital sectors combined, including long-term care facilities (DDD per 1000 inhabitants per day) in 2019 2 | Recommended target reduction |
| NL | 9.5 | 3% |
| AT | 11.6 | 3% |
| EE | 11.8 | 3% |
| SE | 11.8 | 3% |
| DE | 12.6 3 | 9% |
| SI | 13.0 | 9% |
| LV | 13.9 | 9% |
| HU | 14.4 | 9% |
| FI | 14.7 | 9% |
| DK | 15.3 | 9% |
| LT | 16.1 | 9% |
| CZ | 16.9 | 9% |
| HR | 18.8 | 9% |
| PT | 19.3 | 9% |
| SK | 19.3 | 9% |
| BG | 20.7 | 18% |
| MT | 20.7 | 18% |
| LU | 21.1 | 18% |
| BE | 21.4 | 18% |
| IT | 21.7 | 18% |
| IE | 22.8 | 27% |
| PL | 23.6 | 27% |
| ES | 24.9 | 27% |
| FR | 25.1 | 27% |
| RO | 25.8 | 27% |
| CY | 30.1 | 27% |
| EL | 34.1 | 27% |
2.National recommended targets on the percentage of consumption of Access group antibiotics out of consumption of all antibiotics (Access, Watch, Reserve, Unclassified) listed in the AWaRe classification of WHO 4 )
Member State | Percentage of consumption of Access group antibiotics out of consumption of all antibiotics (Access, Watch, Reserve, Unclassified) listed in the AWaRe classification in 2019 5 | Recommended target |
| DK | 79.1 | At least 65% |
| FI | 73.2 | |
| FR | 72.0 | |
| NL | 71.2 | |
| SE | 71.0 | |
| IE | 70.3 | |
| LV | 68.6 | |
| BE | 67.9 | |
| LT | 67.5 | |
| ES | 63.0 | |
| HR | 62.7 | |
| SI | 62.1 | |
| PT | 61.4 | |
| EE | 61.3 | |
| PL | 60.4 | |
| CZ | 60.2 | |
| LU | 59.5 | |
| AT | 58.1 | |
| RO | 52.8 | |
| HU | 50.5 | |
| MT | 49.9 | |
| IT | 48.9 | |
| CY | 48.9 | |
| EL | 46.8 | |
| BG | 45.1 | |
| SK | 42.4 | |
| DE | No data 6 |
3.National recommended targets on incidence of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (number per 100,000 population)
| Member State | Incidence of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (number of bloodstream infections 7 per 100,000 population) in 2019 | Recommended target reduction |
| NL | 0.4 | 3% |
| DK | 0.8 | 3% |
| EE | 0.8 | 3% |
| FI | 1.1 | 3% |
| SE | 1.3 | 3% |
| BG | 1.5 | 3% |
| LV | 1.9 | 6% |
| LU | 2.1 | 6% |
| AT | 2.2 | 6% |
| LT | 2.2 | 6% |
| SI | 2.4 | 6% |
| BE | 2.6 | 6% |
| HR | 2.7 | 6% |
| IE | 3.1 | 6% |
| CZ | 3.1 | 6% |
| DE | 3.6 | 10% |
| MT | 3.8 | 10% |
| HU | 4.2 | 10% |
| ES | 4.2 | 10% |
| PL | 4.3 | 10% |
| EL | 4.6 | 10% |
| SK | 5.0 | 10% |
| FR | 5.6 | 18% |
| CY | 6.9 | 18% |
| PT | 11.4 | 18% |
| IT | 13.6 | 18% |
| RO | 13.7 | 18% |
4.National recommended targets on incidence of third-generation cephalosporin-resistant Escherichia coli bloodstream infections (number per 100,000 population)
Member States | Incidence of third-generation cephalosporin-resistant Escherichia coli bloodstream infections 8 (number per 100,000 population) in 2019 | Recommended target reduction |
| EL | 2.6 | 0% |
| BG | 4.3 | 0% |
| NL | 4.5 | 0% |
| LV | 5.0 | 0% |
| HR | 5.3 | 0% |
| LT | 5.6 | 0% |
| HU | 5.7 | 0% |
| CY | 6.2 | 5% |
| RO | 6.3 | 5% |
| SK | 6.4 | 5% |
| CZ | 6.6 | 5% |
| DK | 6.6 | 5% |
| AT | 7.1 | 10% |
| PL | 7.4 | 10% |
| SI | 7.7 | 10% |
| ES | 7.8 | 10% |
| EE | 7.9 | 10% |
| FI | 8.0 | 10% |
| IE | 8.3 | 10% |
| FR | 8.6 | 10% |
| SE | 9.6 | 10% |
| LU | 10.1 | 12% |
| PT | 10.3 | 12% |
| DE | 12.0 | 12% |
| MT | 12.4 | 12% |
| BE | 13.2 | 12% |
| IT | 23.2 | 12% |
5.National recommended targets on incidence of carbapenem-resistant Klebsiella pneumoniae bloodstream infections (number per 100,000 population)
Member State | Incidence of carbapenem-resistant Klebsiella pneumoniae bloodstream infections 9 (number per 100,000 population) in 2019 | Recommended target reduction |
| EE | 0.00 | 0% |
| LV | 0.00 | 0% |
| NL | 0.02 | 0% |
| SE | 0.03 | 0% |
| SI | 0.05 | 2% |
| FI | 0.06 | 2% |
| DK | 0.07 | 2% |
| CZ | 0.09 | 2% |
| HU | 0.09 | 2% |
| IE | 0.11 | 2% |
| LU | 0.16 | 2% |
| DE | 0.20 | 2% |
| AT | 0.20 | 2% |
| FR | 0.22 | 2% |
| BE | 0.27 | 2% |
| SK | 0.52 | 4% |
| LT | 0.54 | 4% |
| ES | 0.76 | 4% |
| HR | 1.20 | 4% |
| PL | 1.38 | 4% |
| MT | 2.13 | 4% |
| BG | 2.29 | 4% |
| CY | 2.61 | 5% |
| PT | 2.93 | 5% |
| RO | 7.12 | 5% |
| IT | 8.51 | 5% |
| EL | 13.05 | 5% |
(1) Some Member States have made progress in tackling AMR or antimicrobial consumption since the baseline year of 2019.
(2) Data from European Surveillance of Antimicrobial Consumption Network (ESAC-Net). Population data are from Eurostat.
(3) Germany did not report consumption data for the hospital sector to ESAC-Net. Total consumption was estimated based on the EU average proportion of hospital sector consumption as part of total consumption.
(4) https://www.who.int/publications/i/item/2021-aware-classification
(5) Data from European Surveillance of Antimicrobial Consumption Network (ESAC-Net). Population data are from Eurostat.
(6) Germany did not report consumption data for the hospital sector to ESAC-Net. This percentage can therefore not be calculated.
(7) Based on existing data on invasive isolates available from the European Antimicrobial Resistance Surveillance Network (EARS-Net), in which invasive isolates are mostly (>99%) from bloodstream infections with a very small percentage (<1%) of isolates from meningitides. Population data are from Eurostat.
(8) Based on existing data on invasive isolates available from the European Antimicrobial Resistance Surveillance Network (EARS-Net), in which invasive isolates are mostly (>99%) from bloodstream infections with a very small percentage (<1%) of isolates from meningitides. Population data are from Eurostat.
(9) Based on existing data on invasive isolates available from the European Antimicrobial Resistance Surveillance Network (EARS-Net), in which invasive isolates are mostly (>99%) from bloodstream infections with a very small percentage (<1%) of isolates from meningitides. Population data are from Eurostat.
Top
×
Timeline legend
Initial legal act
Another version
Selected version
Selected version application period
Hidden intermediate versions
Version which is applicable today
Future version
All